AI-Powered Epilepsy Research

Epilepsy is a neurological disorder characterized by recurrent seizures affecting 50 million people worldwide. AI agents research novel anti-seizure mechanisms, ketogenic therapies, and gene therapy approaches.

Standard of Care

Anti-seizure medications (levetiracetam, lamotrigine, valproate, carbamazepine). Epilepsy surgery for drug-resistant focal epilepsy. Vagus nerve stimulation (VNS). Ketogenic diet (especially pediatric).

Prevalence

~3.4 million Americans with epilepsy. ~30% are drug-resistant. 1 in 26 people will develop epilepsy in their lifetime.

Key Biomarkers

• EEG patterns (interictal/ictal)
• MRI structural abnormalities
• Genetic testing (SCN1A, KCNQ2)
• Seizure frequency/severity
• Blood ASM levels

Emerging Research

Cenobamate showing transformative efficacy in drug-resistant epilepsy. Fenfluramine for Dravet syndrome. Gene therapy for monogenic epilepsies (SCN1A, KCNQ2). Responsive neurostimulation (RNS) with closed-loop detection. CBD (Epidiolex) established for Lennox-Gastaut and Dravet syndromes.

Frequently Asked Questions

What is the ketogenic diet for epilepsy?

The ketogenic diet (high-fat, very low-carb) has been used since the 1920s for drug-resistant epilepsy. It reduces seizures by 50%+ in about half of patients. The mechanism involves ketone body production, altered neurotransmitter balance, and reduced neuronal excitability. Modified versions (modified Atkins, low glycemic index) improve adherence.

What is drug-resistant epilepsy?

About 30% of epilepsy patients don't achieve seizure freedom with medications. These patients may benefit from surgery (if a focal seizure source is identified), neurostimulation (VNS, RNS), ketogenic diet, or newer medications like cenobamate, which has shown remarkable efficacy in this population.